Keep current on Kinomica Ltd. Discover our latest press releases, announcements and news.

In Other News...

biotrinity 2021 logo

Kinomica are attending OBN’s Biotrinity 2021 conference

20 May 2021

Kinomica is excited to attending OBN’s BioTrinity 2021 conference later this month, and contributing as one of their BioLaunchPad showcase companies.

BioTrinity 2021 is a highly-regarded biopartnering and investment life science conference, aiming to shine a light on new innovation within the industry, as well as inspiring growth and creating opportunities for all of those who attend. 

The delivery of the BioTrinity conference will be in full compliance with all current COVID-19 guidelines, and so will be delivered live in a hybrid format via a dedicated virtual platform and in person at etc. venues Bishopgate, London.

BioLaunchPad is the company showcase platform at BioTrinity 2021, where innovative life sciences companies can present their commercial proposition to the industry, via 5-minute presentations. Our presentation will be recorded and made available on the ‘On Demand’ section of the virtual platform as well.

Kinomica presents a Poster at this year’s online ASCO conference

19 May 2021

The 2021 ASCO (American Society of Clinical Oncology) Annual Meeting features a dynamic programme of educational and scientific sessions, showcasing what is possible when the cancer care community comes together to advance cancer research, treatment and patient care.

Kinomica were delighted to be able to present our Poster (Abstract 7019) with the title “Predictive phosphoproteomic signatures for midostaurin plus chemotherapy response in FLT3 mutant positive acute myeloid leukaemia.”

Our Abstract focused on a study we completed, which tested whether previous phosphosignatures we had identified could group FLT3+ patients based on clinical responses to midostaurin plus chemotherapy.

logo for 2021 ASCO annual meeting

Contact Us!

If you have any questions or need any further information, then please contact the Kinomica team – we are more than happy to help.

“Our groundbreaking technology driven by deep expertise and powerful insights provides a direct snapshot of protein and cell-signalling activity, with data that demonstrates we can predict drug response far more accurately than current gene mutation markers”

Anthony Sullivan, Business Development Director